MDNews - Lower Hudson/Bronx

June 2015

Issue link: https://viewer.e-digitaledition.com/i/521055

Contents of this Issue

Navigation

Page 16 of 23

the release of the antibiotic. They also tested the mixture's ability to fight Bacillus subtilis, Staphylococcus epi- dermidis and Staphylococcus aureus, three common causes of orthopedic bacterial infection. B y d a y s e v en , t he H E R A F I L L bone g ra f t mix ture wa s relea sing 0.42 mg/mL of gentamicin, enough to k i l l St aphylo co cc u s epider m i- dis and Staphylococcus aureus planktonic cells and to meet the threshold of protec- tion against bacterial infection. "Our goal is prevention of infection following bone reconstruction with antibiotics loca lly administered in the fi rst crucial postoperative phase," Dr. Nogler says. With controlled dosing and gradual disbursement, there is no need to remove the antibiotic-enriched bone graft mixture used in this study. The body absorbs it just as it would any other bone graft, mitigating the need for a secondary procedure. Building a Standard Researchers at Innsbruck Medical University plan to continue examining the effi cacy of HERAFILL as an antibiotic delivery agent in bone grafts. "We want to understand the mechani- cal infl uence that different amounts of HERAFILL added to bone chips has on initial stability," Dr. Nogler says. "Further tests should also show how we can com- bine other antibiotics, antimycotics or antiseptics with HERAFILL." Their work may be a boon to a line of scientifi c inquiry that has existed at least since 1947. The fi eld has suffered from a lack of defi nitive conclusions, according to a 2012 review in the International Journal of Biomaterials, due in part to the copious options both for combining the antibiotics with grafting materials and selecting a ratio of antibiotics to graft material. ■ A COAT O F P R OT EC TI O N PROTECTIVE ANTIBIOTIC COATINGS are standard for devices such as stents, but researchers are just beginning to uncover this technology's potential for reducing infection rates in joint replacement patients. One of the challenges of using antibiotic coatings in joints is the need for smooth articulation — the coatings must be effective without gumming up the works. At the Massachusetts Institute of Technology, researchers have attempted to work around this roadblock by adding multiple, thin microlayers of antimicrobial material to implants to avoid bulk. At other research centers, investigators are working toward fi nding the right balance of infection resistance and host cell growth support, testing coatings of silver that repel bacterial growth and looking into the use of biodegradable polymers as coatings for titanium implants. The goal is to develop a well-articulated joint whose antibiotic properties last several weeks but then stop predictably to prevent antibiotic resistance. SPECIAL CLINICAL SECTION: ORTHOPEDICS M D N E W S . CO M ■ MD NEWS Lower Hudson/Bronx | 1 7

Articles in this issue

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - June 2015